Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pramlintide + metreleptin
- Development stage
- Discontinued
- Lead developer
- Bristol Myers Squibb
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
Pramlintide + metreleptin is a combination of two peptide-based drugs, pramlintide (an amylin analog) and metreleptin (a leptin analog), developed as an investigational therapy for obesity. Pramlintide acts by mimicking the effects of amylin, a hormone co-secreted with insulin by pancreatic β-cells, to slow gastric emptying, suppress post-prandial glucagon secretion, and increase satiety. Metreleptin is a recombinant analog of human leptin that binds to and activates the leptin receptor to regulate satiety and energy expenditure. The combination was shown in clinical trials to produce greater weight loss than either agent alone by integrating short-term satiation signaling (amylin) with long-term adiposity signaling (leptin). Development was discontinued after Phase 2 due to commercial reasons despite evidence of robust efficacy in sustained weight loss[1][5][8][2].
- Other names
- pramlintide/metreleptin
02
Targets
AMY (Pancreatic alpha-amylase)AMY3 (Amylin receptor 3)LEPR (Leptin receptor)CALCR (Calcitonin receptor)RAMP1 (Receptor activity-modifying protein 1)RAMP2 (Receptor activity-modifying protein 2)RAMP3 (Receptor activity-modifying protein 3)
Beyond the preview
Go deeper on pramlintide + metreleptin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pramlintide + metreleptin.